Arthrosemid vs. Steroid for the Management Knee Osteoarthritis
A Randomised Control Trial of the Use of an Intraarticular Hydrogel Arthrosemid® vs. Steroid for the Non-operative Management of Moderate to Severe Osteoarthritis
Cappagh National Orthopaedic Hospital
200 participants
Mar 1, 2026
INTERVENTIONAL
Conditions
Summary
This study will be a randomised control trial of the use of intra-articular Arthrosamid® a novel intraarticular hydrogel vs. standard of care (steroid and local anaesthetic) for the non-operative management of knee osteoarthritis.
Eligibility
Inclusion Criteria3
- Adults
- Symptomatic single side knee pain.
- Patients with diagnosis of knee osteoarthritis radiographic Kellgren and Lawrence system OA grade II-III-IV on x ray or MRI.
Exclusion Criteria9
- Inflammatory conditions,
- Cancer,
- acute infection,
- pregnancy and breastfeeding.
- Uncontrolled diabetes mellitus,
- Joint diseases in the knee, such as rheumatoid arthritis or gout, history of knee surgery with metallic implant.
- If patient has undergone knee arthroscopy in past 6 months.
- Intra-articular injection of corticosteroids during the previous 3 months, intra-articular injection of other drugs, such as hyaluronic acid over the previous 1 year.
- Contraindications for intra-articular injection, such as thrombocytopenia, coagulopathy, articular infection of knee, impairment of immunity.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Arthrosamid is a non-biodegradable, 2.5% polyacrylamide hydrogel (iPAAG) injection designed as a long-lasting, non-surgical treatment for knee osteoarthritis. It acts as a synovial implant that provides cushioning, reduces pain, and improves mobility for up to 3-4 years, often delaying the need for knee replacement surgery.
dexamethasone 8mg, methylprednisolone 80mg and bupivacaine 5ml 0.25%, intra articular injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07489521